Post-Bariatric Hypoglycemia Market: Breakthrough Forecast Study Predicts Astounding Growth in the Upcoming Years | Eiger Biopharmaceuticals (Avexitide), Vogenx (Mizagliflozin)

 Breaking News
  • No posts were found

Post-Bariatric Hypoglycemia Market: Breakthrough Forecast Study Predicts Astounding Growth in the Upcoming Years | Eiger Biopharmaceuticals (Avexitide), Vogenx (Mizagliflozin)

October 10
22:12 2023
Post-Bariatric Hypoglycemia Market: Breakthrough Forecast Study Predicts Astounding Growth in the Upcoming Years | Eiger Biopharmaceuticals (Avexitide), Vogenx (Mizagliflozin)
Delveinsight Business Research LLP
As per DelveInsight, the Post-Bariatric Hypoglycemia Market is anticipated to evolve immensely in the coming years owing to the increase in the patient pool and the expected entry of emerging therapies.

DelveInsight’s “Post-Bariatric Hypoglycemia Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Post-Bariatric Hypoglycemia market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The report covers emerging Post-Bariatric Hypoglycemia drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Post-Bariatric Hypoglycemia treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Post-Bariatric Hypoglycemia: An Overview

Bariatric surgery, or weight loss surgery, is a group of surgical procedures designed to help individuals with severe obesity achieve significant and sustained weight loss. These surgeries are typically recommended for individuals unsuccessful in achieving weight loss through nonsurgical methods, such as diet and exercise, and who have obesity-related health conditions.

Post-Bariatric hypoglycemia is the development of hypoglycemia (low blood sugar) following bariatric surgery, such as gastric bypass or sleeve gastrectomy. It typically occurs within a few years after surgery. Several risk factors contribute to Post-Bariatric hypoglycemia, including rapid weight loss, altered gastrointestinal anatomy, increased insulin sensitivity, hyperinsulinemia, and reactive hypoglycemia.

The pathophysiology of Post-Bariatric hypoglycemia is complex and involves several interrelated mechanisms. It is believed to result from alterations in the normal hormonal and metabolic response to food intake following bariatric surgery.

The management of Post-Bariatric hypoglycemia involves dietary modifications, such as consuming small and frequent meals, avoiding high-glycemic index foods, and restricting simple sugars. Medications, including acarbose, diazoxide, or glucagon-like peptide-1 (GLP-1) receptor agonists, may be prescribed to help control blood sugar levels. In severe cases, surgical interventions, such as partial or complete reversal of the bariatric surgery, may be considered.

Few therapies are being investigated for the treatment of Post-Bariatric hypoglycemia. Some key players involved in the development are Vogenx (mizagliflozin) and Eiger BioPharmaceuticals (Avexitide).

Post-Bariatric Hypoglycemia Market Key Facts

  • In 2022, the United States accounted for the largest market size among the 7MM countries, making ~89% of the total market size of the 7MM.

  • Among the 7MM countries, Spain had the market size in 2022, accounting for ~1% of the market size in the 7MM region.

  • In EU4 and the UK region, France accounted for the largest market size, making up ~6% of the total market size of the EU4 region.

  • In 2022, the total Post-Bariatric hypoglycemia (PBH) cases in the United States were ~82,000, projected to increase during the forecast period (2023–2032).

  • The total Post-Bariatric hypoglycemia (PBH) cases in EU4 and the UK were ~21,000 in 2022. The cases will increase during the forecast period (2023–2032).

  • The total number of Post-Bariatric hypoglycemia (PBH) cases in Japan was ~200 in 2022.

  • Various key players are leading the treatment landscape of Post-Bariatric hypoglycemia, such as Vogenx and Eiger Biopharmaceuticals.

Post-Bariatric Hypoglycemia Market

The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Post-Bariatric Hypoglycemia pipeline therapies. It also thoroughly assesses the Post-Bariatric Hypoglycemia market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.

The report gives complete details of the market trend for each marketed Post-Bariatric Hypoglycemia drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.

Post-Bariatric Hypoglycemia Epidemiology Assessment 

The epidemiology section provides insights into the historical, current, and forecasted Post-Bariatric Hypoglycemia epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Post-Bariatric Hypoglycemia epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders. 

The Report Covers the Post-Bariatric Hypoglycemia Epidemiology, Segmented as –

  • Type-Specific Bariatric Surgery Cases

  • Total Post-Bariatric Hypoglycemia (PBH) Cases

  • Post-Bariatric Hypoglycemia (PBH) Cases in Different Types of Bariatric Surgeries

  • Severity-specific Post-Bariatric Hypoglycemia (PBH) Cases

  • Total Treated Cases of Post-Bariatric Hypoglycemia (PBH) in the 7MM 

Post-Bariatric Hypoglycemia Drugs Uptake and Pipeline Development Activities

The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Post-Bariatric Hypoglycemia market or expected to be launched during the study period. The analysis covers the Post-Bariatric Hypoglycemia market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Post-Bariatric Hypoglycemia drugs based on their sale and market share.

The report also covers the Post-Bariatric Hypoglycemia pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Post-Bariatric Hypoglycemia companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Learn How the Post-Bariatric Hypoglycemia Market Will Evolve and Grow by 2032 @

Post-Bariatric Hypoglycemia Therapeutics Analysis

As no approved therapies are available in the market, there is a huge opportunity for pharmaceutical firms to develop targeted and effective therapies for treating Post-Bariatric hypoglycemia. The use of off-label therapies is limited by poor tolerability and lack of efficacy.

Medical nutritional therapy is the first line of treatment for PBH. A strategy of consuming small portions of low glycemic index carbohydrates (30 g of carbohydrates per meal, 15 g per snack), adequate protein consumption (30 g per meal and total of 60–80 g/day), adequate fat consumption (15 g/meal, 5 g/snack), spacing meals 3–4 h apart, avoidance of alcohol, caffeine, and fluids with meals is recommended.

Surgical management may be considered for patients with moderate-to-severe symptoms refractory to nutritional therapy and pharmacotherapy. As with pharmacotherapy, large-scale trials comparing efficacy and safety are yet to be performed; surgical modality depends on the clinician’s preference/expertise, comorbidities, anatomy, and patient choice. Hypoglycemia is a challenging diagnosis.

Post-Bariatric Hypoglycemia Companies Actively Working in the Therapeutics Market Include

  • Vogenx

  • Eiger BioPharmaceuticals

And Many Others

Emerging and Marketed Post-Bariatric Hypoglycemia Therapies Covered in the Report Include:

  • Avexitide: Eiger Biopharmaceuticals

  • Mizagliflozin: Vogenx

And Many More

Other than the above-mentioned therapies, companies such as Zealand Pharma are developing a dasiglucagon mini-dose pen for the potential treatment of exercise-induced hypoglycemia in people living with T1D and for people who suffer from meal-induced hypoglycemia following gastric bypass surgery (post-bariatric hypoglycemia, or PBH).

Download the Sample Report to Learn More About the Key Companies and Emerging Therapies @

Table of Content (TOC)

1. Key Insights

2. Executive Summary 

3. Post-Bariatric Hypoglycemia Competitive Intelligence Analysis

4. Post-Bariatric Hypoglycemia Market Overview at a Glance

5. Post-Bariatric Hypoglycemia Disease Background and Overview

6. Post-Bariatric Hypoglycemia Patient Journey

7. Post-Bariatric Hypoglycemia Patient Population and Epidemiology Trends (In the US, EU5, and Japan)

8. Post-Bariatric Hypoglycemia Treatment Algorithm, Current Treatment, and Medical Practices

9. Post-Bariatric Hypoglycemia Unmet Needs

10. Key Endpoints of Post-Bariatric Hypoglycemia Treatment

11. Post-Bariatric Hypoglycemia Marketed Therapies

12. Post-Bariatric Hypoglycemia Emerging Drugs and Latest Therapeutic Advances

13. Post-Bariatric Hypoglycemia Seven Major Market Analysis

14. Attribute Analysis

15. Post-Bariatric Hypoglycemia Market Outlook (In US, EU5, and Japan)

16. Post-Bariatric Hypoglycemia Companies Active in the Market

17. Post-Bariatric Hypoglycemia Access and Reimbursement Overview

18. KOL Views on the Post-Bariatric Hypoglycemia Market

19. Post-Bariatric Hypoglycemia Market Drivers

20. Post-Bariatric Hypoglycemia Market Barriers

21. Appendix

22. DelveInsight Capabilities

23. Disclaimer

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Request the Sample PDF to Learn More About the Key Offerings of the Report @



About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Other Trending Healthcare Reports by DelveInsight

Bone Neoplasms Market

“Bone Neoplasms Market Insights, Epidemiology, and Market Forecast-2032” report deliver an in-depth understanding of the historical and forecasted epidemiology as well as the Bone Neoplasms market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Bone Neoplasms market.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States

Related Articles